• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pulmonary hypertension aetiologies in different parts of the world.世界各地肺动脉高压的病因。
Int J Cardiol Congenit Heart Dis. 2025 Apr 15;20:100586. doi: 10.1016/j.ijcchd.2025.100586. eCollection 2025 Jun.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.1990-2021年全球、区域和国家肺动脉高压负担:全球疾病负担研究2021的系统分析
Lancet Respir Med. 2025 Jan;13(1):69-79. doi: 10.1016/S2213-2600(24)00295-9. Epub 2024 Oct 18.
4
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球疾病、伤害和危险因素负担研究 2021 年,1990-2021 年全球 204 个国家和地区及 811 个次国家地区 371 种疾病和伤害的发病率、患病率、伤残损失生命年(YLDs)、伤残调整生命年(DALYs)以及健康期望寿命(HALE):系统分析
Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17.
5
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球 204 个国家和地区及 811 个亚级行政区 1990 年至 2021 年 288 种死因及预期寿命的归因分析:全球疾病负担研究 2021 系统分析。
Lancet. 2024 May 18;403(10440):2100-2132. doi: 10.1016/S0140-6736(24)00367-2. Epub 2024 Apr 3.
6
Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.全球、地区和国家慢性阻塞性肺疾病和哮喘的死亡、患病率、残疾调整生命年以及与残疾相关的生命年,1990-2015 年:2015 年全球疾病负担研究的系统分析。
Lancet Respir Med. 2017 Sep;5(9):691-706. doi: 10.1016/S2213-2600(17)30293-X. Epub 2017 Aug 16.
7
What was the Epidemiology and Global Burden of Disease of Hip Fractures From 1990 to 2019? Results From and Additional Analysis of the Global Burden of Disease Study 2019.1990 年至 2019 年髋部骨折的流行病学和全球疾病负担是怎样的?来自 2019 年全球疾病负担研究的结果及进一步分析。
Clin Orthop Relat Res. 2023 Jun 1;481(6):1209-1220. doi: 10.1097/CORR.0000000000002465. Epub 2022 Nov 2.
8
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、区域和国家层面 195 个国家和地区 1990 年至 2017 年 354 种疾病和伤害导致的发病率、患病率和伤残损失寿命年:基于 2017 年全球疾病负担研究的系统分析。
Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.
9
The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017.全球、地区和国家 195 个国家/地区 1990-2017 年胃癌负担:2017 年全球疾病负担研究的系统分析。
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54. doi: 10.1016/S2468-1253(19)30328-0. Epub 2019 Oct 21.
10
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.1990—2019年全球、区域和国家的卒中负担及其风险因素:全球疾病负担研究2019的系统分析
Lancet Neurol. 2021 Oct;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3.

引用本文的文献

1
Advances in diagnosis and patient profiling in pulmonary arterial hypertension for precision medicine.肺动脉高压精准医学中诊断与患者特征分析的进展
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251367312. doi: 10.1177/17534666251367312. Epub 2025 Aug 29.
2
Pulmonary Hypertension Among Individuals Living With Hemoglobinopathies: A Systematic Review.血红蛋白病患者中的肺动脉高压:一项系统评价。
Cureus. 2025 Jul 18;17(7):e88234. doi: 10.7759/cureus.88234. eCollection 2025 Jul.

本文引用的文献

1
Trends and levels of the global, regional, and national burden of pulmonary arterial hypertension from 1990 to 2021: findings from the global burden of disease study 2021.1990年至2021年全球、区域和国家肺动脉高压负担的趋势与水平:全球疾病负担研究2021的结果
Front Med (Lausanne). 2024 Dec 10;11:1515961. doi: 10.3389/fmed.2024.1515961. eCollection 2024.
2
Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.1990-2021年全球、区域和国家肺动脉高压负担:全球疾病负担研究2021的系统分析
Lancet Respir Med. 2025 Jan;13(1):69-79. doi: 10.1016/S2213-2600(24)00295-9. Epub 2024 Oct 18.
3
Prevalence and significance of pulmonary hypertension among hospitalized patients with left heart disease.住院左心疾病患者肺动脉高压的患病率及意义。
Respir Med. 2024 Nov-Dec;234:107817. doi: 10.1016/j.rmed.2024.107817. Epub 2024 Sep 23.
4
Pulmonary hypertension associated with left heart disease.与左心疾病相关的肺动脉高压。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01344-2024. Print 2024 Oct.
5
Definition, classification and diagnosis of pulmonary hypertension.肺动脉高压的定义、分类和诊断。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01324-2024. Print 2024 Oct.
6
The Seventh World Symposium on Pulmonary Hypertension: our journey to Barcelona.第七届世界肺动脉高压研讨会:我们前往巴塞罗那的旅程。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01222-2024. Print 2024 Oct.
7
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.肺动脉高压的临床试验设计、终点和新兴疗法。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01205-2024. Print 2024 Oct.
8
Prevalence of Pulmonary Hypertension among Sudanese Patients with Sickle Cell Disease.苏丹镰状细胞病患者中肺动脉高压的患病率
Open Respir Med J. 2024 May 21;18:e18743064292252. doi: 10.2174/0118743064292252240422100911. eCollection 2024.
9
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment.左心疾病相关肺动脉高压:表型与治疗。
Eur J Intern Med. 2024 Nov;129:1-15. doi: 10.1016/j.ejim.2024.07.030. Epub 2024 Aug 1.
10
Pulmonary hypertension across the spectrum of left heart and lung disease.左心和肺部疾病相关肺动脉高压
Eur J Heart Fail. 2024 Jul;26(7):1642-1651. doi: 10.1002/ejhf.3302. Epub 2024 Jun 4.

世界各地肺动脉高压的病因。

Pulmonary hypertension aetiologies in different parts of the world.

作者信息

Butrous Ghazwan

机构信息

Cardiopulmonary Sciences, School of Pharmcy, University of Kent, Canterbury, CT2 7NZ, UK.

Pulmonary Vascular Research Institute, 5 Tanner Street, London, SE1 3LE, UK.

出版信息

Int J Cardiol Congenit Heart Dis. 2025 Apr 15;20:100586. doi: 10.1016/j.ijcchd.2025.100586. eCollection 2025 Jun.

DOI:10.1016/j.ijcchd.2025.100586
PMID:40330318
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12054017/
Abstract

Pulmonary hypertension is a serious condition characterised by elevated blood pressure in the pulmonary arteries, caused by various aetiologies and via different pathological processes. Over the past seventy years, our understanding and management of this disorder have greatly improved, resulting in increased diagnosis and effective clinical management. Current epidemiological estimates are challenged by the increased awareness of this condition and the changing definitions and classification systems. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has also shown temporal changes in the epidemiology of pulmonary hypertension over the last thirty years, contributing to regional variations in prevalence and incidence. This review explores the complexities of global and regional variations in different types of pulmonary hypertension reported through many registries, databases and regional studies. Although these tools can help estimate prevalence and incidences, they may also underestimate the actual number of cases due to the continuously changing understanding of the condition and increase awareness globally. Therefore, continued research, international collaboration, and standardised data collection are essential for achieving a more accurate global view of pulmonary hypertension and developing effective management strategies for this serious condition that significantly impacts general health.

摘要

肺动脉高压是一种严重的病症,其特征为肺动脉血压升高,由多种病因并通过不同的病理过程引起。在过去七十年里,我们对这种疾病的认识和管理有了很大改善,从而使诊断增加且临床管理有效。目前的流行病学估计受到对该病症认识的提高以及定义和分类系统不断变化的挑战。全球疾病、伤害及危险因素负担研究(GBD)也显示了过去三十年来肺动脉高压流行病学的时间变化,这导致了患病率和发病率的区域差异。本综述探讨了通过许多登记处、数据库和区域研究报告的不同类型肺动脉高压的全球和区域差异的复杂性。尽管这些工具有助于估计患病率和发病率,但由于对该病症的理解不断变化以及全球意识的提高,它们可能也会低估实际病例数。因此,持续的研究、国际合作和标准化的数据收集对于更准确地了解全球肺动脉高压情况以及制定针对这种严重影响总体健康的病症的有效管理策略至关重要。